Spyre Therapeutics Inc. Asset Resilience Ratio
Spyre Therapeutics Inc. asset resilience ratio. Spyre Therapeutics Inc. (SYRE) has an Asset Resilience Ratio of 83.83% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Spyre Therapeutics Inc. (SYRE) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Spyre Therapeutics Inc. (2015–2025)
Asset resilience ratio of Spyre Therapeutics Inc. from 2015 to 2025. This chart shows how Spyre Therapeutics Inc.'s Asset Resilience Ratio has changed over time. Read SYRE total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Spyre Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SYRE total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $983.34 Million | 83.83% |
| Total Liquid Assets | $983.34 Million | 83.83% |
Asset Resilience Insights
- Very High Liquidity: Spyre Therapeutics Inc. maintains exceptional liquid asset reserves at 83.83% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Spyre Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Spyre Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Spyre Therapeutics Inc. Asset Resilience Ratio by Year (2015–2025)
Spyre Therapeutics Inc. asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Spyre Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 86.25% | $670.81 Million | $777.78 Million | +1.83pp |
| 2024-12-31 | 84.42% | $513.66 Million | $608.48 Million | +40.43pp |
| 2023-12-31 | 43.99% | $150.38 Million | $341.86 Million | +14.69pp |
| 2022-12-31 | 29.30% | $20.85 Million | $71.14 Million | -41.64pp |
| 2021-12-31 | 70.94% | $77.99 Million | $109.93 Million | +36.18pp |
| 2020-12-31 | 34.76% | $56.18 Million | $161.62 Million | -28.59pp |
| 2019-12-31 | 63.35% | $52.70 Million | $83.18 Million | -3.61pp |
| 2018-12-31 | 66.96% | $52.05 Million | $77.74 Million | +0.12pp |
| 2017-12-31 | 66.84% | $37.48 Million | $56.08 Million | +43.35pp |
| 2016-12-31 | 23.49% | $15.75 Million | $67.06 Million | +13.74pp |
| 2015-12-31 | 9.75% | $3.77 Million | $38.65 Million | -- |
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative … Read more